<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>C-terminal <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> in nucleophosmin (NPM), a nucleolar shuttling protein that binds p53 and p19(<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">Arf</z:e>), were recently described in karyotypically <z:mpath ids='MPATH_458'>normal</z:mpath> <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We analysed primary marrow samples from 150 patients with various <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid disorders for mutations in the NPM1 gene encoding NPM </plain></SENT>
<SENT sid="2" pm="."><plain>NPM1 mutations (tetranucleotide duplication) were detected in three patients, <z:hpo ids='HP_0000001'>all</z:hpo> of whom had <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_501'>myelomonocytic leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) and a short (&lt;1 year) survival, with <z:hpo ids='HP_0003678'>rapid progression</z:hpo> to overt <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> other patients were NPM1-<z:mp ids='MP_0002169'>wild type</z:mp> in the region analysed </plain></SENT>
<SENT sid="4" pm="."><plain>In conclusion, C-terminal NPM mutations are uncommon in <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0002664'>neoplasia</z:hpo>, but if present may represent an evolving leukaemic clone </plain></SENT>
</text></document>